SynthesisBMC neurology2026
Clot composition analysis in ischemic stroke of cancer patients: a systematic review.
Synthesis in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Case Report: Recurrent cerebral embolism secondary to direct cardiac invasion by lung adenocarcinoma.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCancer patients are at high risk of ischemic stroke (IS) and worse outcomes. Endovascular thrombectomy (EVT) has made the analysis of retrieved clots available. This review aimed to identify studies and case reports on IS clot analysis in cancer patients (PROSPERO Registry Number CRD420251042353).
methodsThe databases of PubMed/MEDLINE and SCOPUS were systematically searched for studies and case reports involving pathological analysis of clots (from EVT or autopsy) retrieved from IS patients with cancer, following the PRISMA guidelines. Studies on children, other retrieved materials, benign tumors, or where the results of cancer patients were unavailable were excluded.
results23 case reports and 10 studies with larger clot numbers were included. Seventeen case reports referred to tumor embolism, 3 to cancer-related thrombosis (Trousseau syndrome), 2 to mucin embolism, and 1 to post-radiation stenosis. Most clots had an atypical white appearance, with tumor cells and mucin in tumor or mucin embolism respectively, or a platelet predominance for cancer-related thrombosis. Seven of 8 larger-scale studies reported significantly higher platelet and lower red blood cell proportions for clots in cancer patients, and 5 studies showed no increased percentages of white blood cells or neutrophil extracellular traps.
conclusionThe available studies were heterogeneous, and relatively small. However, preponderance of studies shows the clots of cancer patients tend to be white and predominantly platelet-rich. Atypical appearances also occur in cases of tumor or mucin embolism. These findings bear diagnostic and therapeutic implications after IS in cancer patients, including tumor work-up in platelet-rich clots and no other identifiable cause.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.